Biologic Therapies (anti–IL-4Rα and IL-5 Inhibitors): Although eosinophil levels in COPD are not generally elevated compared to the general population, a subset of patients displays eosinophilic inflammation and features of type 2 (T2) inflammation [88,89]. The gene discussed is IL4R; the disease is chronic obstructive pulmonary disease.